Issue link: https://www.e-digitaleditions.com/i/962670
8 April 2018 Tablets & Capsules tion information (or the exchange of product tracing information between partners), transaction history, and transaction statements (or product tracing information). Specifically, the draft states that by 2023, all transac- tion information will be exchanged only electronically. It also recom- mends documentation practices a trading partner can use to meet its product tracing obligations, includ- ing situations where the trading part- ner is legally allowed to omit certain product tracing information. T h e s e c o n d d r a f t g u i d a n c e , "Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act," describes the FDA's current understanding of the terms "counterfeit", "diverted", "fraud- ulent transaction", and "unfit for dis- tribution" and defines what consti- tutes a "suspect" or "illegitimate" product. This draft is intended to help trading partners meet their veri- fication obligations, which include notifying the agency. PRUK project will train children to swallow oral solid dosage forms L O N D O N , U K — P h a r m a c y Research UK (PRUK) plans to launch a "Pill School" program, which will train young patients to take tablets and capsules at the Evelina London Children's hospital, which helped fund the study. During the course of this program, researchers will identify the proportion of children at the hos- pital who can be trained to take solid oral dosage medication rather than liquid medicines. VCU School of Engineering receives commercialization grant RICHMOND, VA—GO Virginia, an economic development initiative, has awarded a $500,000 grant to the Virginia Commonwealth University (VCU) School of Engineering to sup- port VCU's commercial efforts to implement FDA-approved, sustain- able pharmaceutical manufacturing in Virginia. VCU will partner with Bright Path Pharmaceuticals, combin- ing VCU's research with the compa- ny's technologies to build low-cost Acid Resistant Vegetable Capsules ) ' u n. , u, ' . ' AN EXCELLENT CHOICE FOR DELIVERY OF ACID-SENSITIVE ACTIVE INGREDIENDTS . . . <> . BioCaps Enterprises, Inc. www.biocaps.net • info@biocaps.net US Patent 9452141 Ensure Tablet Integrity! CT3 ™ Tester Best value in a stand-alone instrument for quick Pass/Fail Tests Wide range of probes and fixtures: TA-TCF Tablet Compression Fixture to assure tablet integrity TA-TCA Tablet Coating Adhesion Fixture confirms coating adhesion Offers the most test report selections in its class TEL 800-628-8139 or 508-946-6200 www.belusa.com Tablet Coating Adhesion